CliffBio
small molecule

KYNMOBI

APOMORPHINE HYDROCHLORIDE

Loss of exclusivityApril 2036latest FDA-listed patent expiry
CompanySumitomo Pharma America →See this company's full patent-cliff portfolio

Drug detail

Brand nameKYNMOBI
Active ingredientAPOMORPHINE HYDROCHLORIDE
Strength10MG
Dosage formFILM
RouteSUBLINGUAL
ModalitySmall molecule
FDA approvalMay 2020
Marketing statusDISCN

Listed patents

PatentExpiresType
10449146April 2036use U-2825
10959943April 2036use U-2825
11419769December 2031product
8846074December 2031product
8414922December 2031product
9044475June 2030product
10420763June 2030product
9669021June 2030use U-2825
9669019June 2030product
9283219June 2030product
9326981June 2030use U-2825
10821074August 2029product

More from Sumitomo Pharma America

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

KYNMOBI patent cliff — loss of exclusivity April 2036 | CliffBio